Industry News

Stellar Biotechnologies, Inc., the leader in sustainable manufacture of Keyhole Limpet Hemocyanin, announced today that it has closed its previously announced $6.75 million sale of 1,687,500 common shares in a registered direct offering and unregistered warrants to purchase up to 1,265,626 unregistered common shares in a private placement. The combined purchase price for one registered common share and one unregistered warrant to purchase..."/>
Stellar Biotechnologies Announces Closing of Registered Direct Offering
AMSURG Corp. today announced that its management will participate in the Cantor Fitzgerald 2 nd Annual Healthcare Conference on Tuesday, July 12, 2016, in New York. In connection with the conference, there will be an on-line simulcast and a replay of the presentation available at the Company’ s web site starting at 10:45 a.m. Eastern Time/ 9:45 a.m. The live audio webcast and replay of the presentation will be available on the Company’ s website by going to..."/>
AMSURG Corp. to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference
Retractable Technologies, Inc. announced today that its Board of Directors has declared dividends to holders of its Series I Class B and Series II Class B Convertible Preferred Stock in the amounts of $12,312.50 and $42,800.00, respectively. The dividend amount is $0.125 per share for Series I Class B shareholders and $0.25 per share for Series II Class B shareholders. Dividends have accrued at 10% per annum and cover amounts in arrears from April 1, 2016..."/>
Retractable Technologies, Inc. Declares Dividends to Series I and II Class B Convertible Preferred Stock Shareholders
NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system disorders, today announced the appointments of Tami Yardeni as Chief Operating Officer and Eran Shor as Vice President Devices.. Yardeni joins us from Teva Pharmaceutical Industries, where she worked for the past 17 years, most recently as VP, Head of Global Clinical Operation, Global R&D. In this position she was responsible for the operational..."/>
NeuroDerm Announces Additions to Management Team
TruBridge Announces New Midwest Customer Service Center
AMSURG Corp. today announced it will release its second quarter 2016 financial results on Tuesday, August 2, 2016, after the market closes. The Company will also host a conference call at 5:00 p.m. Eastern Time that same day. The live broadcast of AMSURG Corp.’ s quarterly conference call will be available on-line by going to http://www.amsurg.com and clicking on the link to Investor Relations."/>
AMSURG Corp. Sets Earnings Release and Conference Call Dates for Second Quarter 2016 Results
Tenet Healthcare Corporation plans to report results for its second quarter ended June 30, 2016 after the market close on Monday, August 1, 2016.. The company will host a conference call the following morning, Tuesday, August 2, at 10 a.m. ET for management to discuss the results."/>
Tenet to Report Second Quarter Results on August 1
Cross Country Healthcare, Inc. will hold its quarterly conference call to discuss its second quarter 2016 financial results on Thursday, August 4, 2016 at 9:00 a.m. Eastern Time. Cross Country Healthcare, Inc. intends to distribute its earnings press release after the close of business on Wednesday, August 3, 2016.. This call will be webcast live and can be accessed at the Company’ s website at www.crosscountryhealthcare.com or by dialing 800-857-6331 from..."/>
Cross Country Healthcare Announces Second Quarter 2016 Earnings Release Date and Conference Call Information
Cipher Pharmaceuticals Inc. responded today to an Early Warning Report filed on July 5, 2016 by 1207407 Ontario Limited, a company wholly owned by Dr. The Special Committee, comprised of directors Stephen Wiseman, Thomas Wellner, William Claypool and Stefan Aigner, was established to address issues of the type referred to in the EWR. Cipher welcomes the opinions of its shareholders and actively seeks..."/>
Special Committee of Cipher Pharmaceuticals Responds to Early Warning Report Filed by 1207407 Ontario Limited
Cipher Pharmaceuticals Inc. responded today to an Early Warning Report filed on July 5, 2016 by 1207407 Ontario Limited, a company wholly owned by Dr. The Special Committee, comprised of directors Stephen Wiseman, Thomas Wellner, William Claypool and Stefan Aigner, was established to address issues of the type referred to in the EWR. Cipher welcomes the opinions of its shareholders and..."/>
Special Committee of Cipher Pharmaceuticals Responds to Early Warning Report Filed by 1207407 Ontario Limited
Trovagene, Inc., a developer of circulating tumor DNA molecular diagnostics, today announced the initiation of a multi-phased collaborative research program with the University of Michigan Comprehensive Cancer Center utilizing the Trovera™ KRAS ctDNA liquid biopsy test. Pancreatic cancer is now the third leading cause of cancer-related death in the U.S. with an 8% relative 5- year survival rate. At present, surgery offers the only..."/>
Trovagene and University of Michigan Enter into Collaboration for Monitoring and Early Detection of Pancreatic Cancer
Pulmatrix, Inc., a pharmaceutical company developing innovative inhaled drugs, today announced that Chief Executive Officer Robert Clarke, PhD, has described advances in inhaled drug delivery in an interview with News Medical, an online medical information provider. "Delivering drugs to the lungs via inhalation has a number of potential advantages over traditional routes of administration like pills or injections," Dr."/>
Pulmatrix's iSPERSE™ Focus of Interview with News Medical
LivaNova PLC, a market-leading medical technology company, today announced a new organizational structure designed to strengthen execution and accountability of its business franchises, promote collaboration across the global organization and support long-term profitable growth. "When LivaNova was formed in late 2015, we communicated our commitment to grow our medical device portfolio through innovative product development and global..."/>
LivaNova PLC Sets Operating Model and Supporting Organization
LivaNova PLC, a market-leading medical technology company, today announced a new organizational structure designed to strengthen execution and accountability of its business franchises, promote collaboration across the global organization and support long-term profitable growth.. “When LivaNova was formed in late 2015, we communicated our commitment to grow our medical device portfolio through innovative product development and global..."/>
LivaNova PLC Sets Operating Model and Supporting Organization
OncBioMune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to inform shareholders of results of pre-clinical research that support further development of the Company's patented, novel paclitaxel gallium transferrin technology for the treatment of multiple types of cancer. OncBioMune first tested PGT against a series of human..."/>
OncBioMune Research Shows Activity of PGT Technology in a Mammary Cancer Animal Model
SCYNEXIS, Inc. today announced that the Company will present at Cantor Fitzgerald’ s 2 nd Annual Healthcare Conference at Le Parker Meridien New York on Tuesday, July 12, 2016 at 9:00 a.m. ET.. A live webcast will be available on the investors section of the Company's website: www.scynexis.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following..."/>
SCYNEXIS, Inc. to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials722 Articles
Consumer Discretionary632 Articles
Information Technology626 Articles
Industrials467 Articles
Health Care368 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.